Passa al contenuto
Merck
Tutte le immagini(3)

Key Documents

PLA0185

Sigma-Aldrich

Rabbit anti-BRCA1 Antibody, Affinity Purified

Powered by Bethyl Laboratories, Inc.

Sinonimo/i:

BRCA1/BRCA2-containing complex, BRCAI, BRCC1, BROVCA1, FANCS, Fanconi anemia, IRIS, PNCA4, PPP1R53, PSCP, RING finger protein 53, RNF53, breast and ovarian cancer susceptibility protein 1, breast and ovarian cancer sususceptibility protein 1, breast cancer 1, complementation group S, early onset, early onset breast cancer 1, protein phosphatase 1, regulatory subunit 53, subunit 1, truncated BRCA1, truncated breast and ovarian cancer susceptibility protein 1, truncated breast and ovarian cancer sususceptibility protein 1, truncated breast cancer type 1 susceptibility protein

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12352203
NACRES:
NA.41

Origine biologica

rabbit

Livello qualitativo

Forma dell’anticorpo

affinity purified immunoglobulin

Tipo di anticorpo

primary antibodies

Grado

Powered by Bethyl Laboratories, Inc.

Reattività contro le specie

human

Concentrazione

1 mg/mL

tecniche

immunohistochemistry: 1:500- 1:2,000
immunoprecipitation (IP): 2-10 μg/mg
western blot: 1:500- 1:2,500

Numero d’accesso

NP_009225.1

N° accesso UniProt

Condizioni di spedizione

wet ice

Temperatura di conservazione

2-8°C

modifica post-traduzionali bersaglio

unmodified

Informazioni sul gene

rabbit ... BRCA1(672)

Categorie correlate

Immunogeno

The epitope recognized by PLA0185 maps to a region between residue 250 and 300 of human breast cancer 1 using the numbering given in entry NP_009225.1 (GeneID 672).

Stato fisico

Tris-citrate/phosphate buffer, pH 7 to 8 containing 0.09% Sodium Azide

Altre note

BRCA1 was identified as a gene with germline mutations that predisposes women to breast and ovarian cancer. The BRCA1 tumor suppressor is a large protein that has been demonstrated to interact with a multitude of proteins involved in the DNA damage response and cell cycle checkpoints to maintain genomic integrity. BRCA1 functions by regulating the activities of its interacting proteins which mediate processes such as gene transcription, gene repression, protein phosphorylation, and ubiquitination.

Esclusione di responsabilità

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Non trovi il prodotto giusto?  

Prova il nostro Motore di ricerca dei prodotti.

Codice della classe di stoccaggio

12 - Non Combustible Liquids

Classe di pericolosità dell'acqua (WGK)

nwg

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Feng Bai et al.
Cancer research, 74(21), 6161-6172 (2014-09-23)
BRCA1 mutation carriers are predisposed to developing basal-like breast cancers with high metastasis and poor prognosis. Yet, how BRCA1 suppresses formation of basal-like breast cancers is still obscure. Deletion of p18(Ink4c) (p18), an inhibitor of CDK4 and CDK6, functionally inactivates
Bárbara Alcaraz Silva et al.
The Journal of biological chemistry, 289(33), 22771-22784 (2014-07-02)
Chromosome ends contain nucleoprotein structures known as telomeres. Damage to chromosome ends during interphase elicits a DNA damage response (DDR) resulting in cell cycle arrest. However, little is known regarding the signaling from damaged chromosome ends (designated here as "TIPs")
Qing Xia et al.
International journal of oncology, 44(3), 735-744 (2014-01-01)
Breast cancer is one of the most common malignancies in women. Approximately 15% of the patients belong to the triple-negative breast cancer (TNBC) group, and have the disadvantage of not benefiting from currently available receptor-targeted systemic therapies. Some cancers in

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.